… LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib
as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the …

… ErbB family blocker, afatinib, has a potential … afatinib significantly prolonged progression-free
and overall survival compared with erlotinib in patients with squamous cell lung carcinoma. …

… -up of OS in the afatinib arm (7.9 months) was significantly longer as compared to erlotinib
(6.8 … , which means that patients on afatinib lived longer than those on erlotinib. In addition, the …

… 17.3 months for gefitinib, 12.4 months for erlotinib, and 23.3 months for afatinib (P< 0.001).
In … (HR) of afatinib was 0.63 (95% CI, 0.47–0.83) compared with gefitinib or erlotinib. In the …

… Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-…
-cell lung cancer (NSCLC), there are very few clinical data comparing afatinib and erlotinib …

… The results from the present study have shown that although gefitinib, erlotinib, and afatinib
… at disease progression between gefitinib or erlotinib and afatinib. These results require …

… of afatinib plus cetuximab compared with afatinib or erlotinib alone … cancer mouse models.
We hypothesized that the combination of afatinib and cetuximab would be superior to afatinib …

… of afatinib, gefitinib, and erlotinib for elderly patients with epidermal growth factor receptor
(EGFR)-mutated advanced non-small-cell lung cancer (… of afatinib, gefitinib, and erlotinib were …

… The Lux-Lung 4 study 21 was a phase II trial of afatinib in patients with advanced NSCLC
who progressed after prior treatment with erlotinib or gefitinib, which is similar to our study. In …

… Sorafenib and sunitinib are orally active multikinase inhibitors approved for the treatment
of hepatocellular carcinoma and renal cell carcinoma, respectively [41,42]. Crizotinib is an …